BELVIQ XR is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Lorcaserin Hydrochloride Hemihydrate.
Product ID | 62856-535_3097271d-6dae-4dce-91c2-783e31678eb6 |
NDC | 62856-535 |
Product Type | Human Prescription Drug |
Proprietary Name | BELVIQ XR |
Generic Name | Lorcaserin Hydrochloride Hemihydrate |
Dosage Form | Tablet, Film Coated, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2016-07-15 |
Marketing Category | NDA / NDA |
Application Number | NDA208524 |
Labeler Name | Eisai Inc. |
Substance Name | LORCASERIN HYDROCHLORIDE HEMIHYDRATE |
Active Ingredient Strength | 20 mg/1 |
Pharm Classes | Serotonin-2c Receptor Agonist [EPC],Serotonin 2c Receptor Agonists [MoA],Cytochrome P450 2D6 Inhibitors [MoA] |
DEA Schedule | CIV |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2016-07-15 |
Marketing End Date | 2022-05-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA208524 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-07-15 |
Ingredient | Strength |
---|---|
LORCASERIN HYDROCHLORIDE HEMIHYDRATE | 20 mg/1 |
SPL SET ID: | 7cbbb12f-760d-487d-b789-ae2d52a3e01f |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
62856-535 | BELVIQ XR | lorcaserin hydrochloride hemihydrate |
62856-529 | Belviq | lorcaserin hydrochloride hemihydrate |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
BELVIQ XR 86693918 4908131 Live/Registered |
EISAI INC. 2015-07-15 |
BELVIQ XR 86693911 4922297 Live/Registered |
Arena Pharmaceuticals GmbH 2015-07-15 |
BELVIQ XR 86330779 4695303 Live/Registered |
EISAI INC. 2014-07-08 |